CA3027118C - Compositions and methods for the treatment of cancer - Google Patents

Compositions and methods for the treatment of cancer Download PDF

Info

Publication number
CA3027118C
CA3027118C CA3027118A CA3027118A CA3027118C CA 3027118 C CA3027118 C CA 3027118C CA 3027118 A CA3027118 A CA 3027118A CA 3027118 A CA3027118 A CA 3027118A CA 3027118 C CA3027118 C CA 3027118C
Authority
CA
Canada
Prior art keywords
formula
cancer
administration
compositions
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3027118A
Other languages
English (en)
French (fr)
Other versions
CA3027118A1 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of CA3027118A1 publication Critical patent/CA3027118A1/en
Application granted granted Critical
Publication of CA3027118C publication Critical patent/CA3027118C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3027118A 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer Active CA3027118C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201641022026 2016-06-28
IN201641022026 2016-06-28
IN201641025259 2016-07-22
IN201641025259 2016-07-22
IN201741006185 2017-02-21
IN201741006185 2017-02-21
PCT/IB2017/052814 WO2018002739A1 (en) 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA3027118A1 CA3027118A1 (en) 2018-01-04
CA3027118C true CA3027118C (en) 2023-08-15

Family

ID=60785109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027118A Active CA3027118C (en) 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer

Country Status (14)

Country Link
US (2) US10858349B2 (enrdf_load_stackoverflow)
EP (1) EP3452044A4 (enrdf_load_stackoverflow)
JP (1) JP6950972B2 (enrdf_load_stackoverflow)
KR (1) KR102306412B1 (enrdf_load_stackoverflow)
CN (1) CN109414438A (enrdf_load_stackoverflow)
AU (3) AU2017286852B2 (enrdf_load_stackoverflow)
BR (1) BR112018076257A2 (enrdf_load_stackoverflow)
CA (1) CA3027118C (enrdf_load_stackoverflow)
IL (2) IL263563A (enrdf_load_stackoverflow)
MX (1) MX384144B (enrdf_load_stackoverflow)
RU (1) RU2770081C2 (enrdf_load_stackoverflow)
SG (1) SG11201810947PA (enrdf_load_stackoverflow)
WO (1) WO2018002739A1 (enrdf_load_stackoverflow)
ZA (1) ZA201808232B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021001652A2 (pt) * 2018-08-03 2021-05-04 Cellix Bio Private Limited composto e composição farmacêutica
EP3679952A1 (en) * 2019-01-10 2020-07-15 Université de Strasbourg Nanoemulsions encapsulating prodrugs
WO2022043902A1 (en) * 2020-08-29 2022-03-03 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (enrdf_load_stackoverflow) * 1992-12-18 1995-08-21 Hoffmann La Roche
JPH1192386A (ja) * 1997-09-17 1999-04-06 Nikken Chem Co Ltd ５−フルオロウリジン誘導体を有効成分とする抗癌剤
EP1311524A2 (en) * 2000-08-09 2003-05-21 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
UA107651C2 (en) * 2008-08-01 2015-02-10 Dow Agrosciences Llc Use of 5-fluorocytosine as a fungicide
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
US10463684B2 (en) * 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds

Also Published As

Publication number Publication date
CN109414438A (zh) 2019-03-01
MX2019000279A (es) 2019-08-01
JP2019519563A (ja) 2019-07-11
IL263563A (en) 2019-01-31
IL280587A (en) 2021-03-25
ZA201808232B (en) 2019-09-25
RU2770081C2 (ru) 2022-04-14
KR20190034539A (ko) 2019-04-02
AU2023208158A1 (en) 2023-08-17
MX384144B (es) 2025-03-14
RU2019100713A3 (enrdf_load_stackoverflow) 2021-02-08
NZ749512A (en) 2021-08-27
JP6950972B2 (ja) 2021-10-20
US20190292171A1 (en) 2019-09-26
CA3027118A1 (en) 2018-01-04
KR102306412B1 (ko) 2021-09-28
EP3452044A1 (en) 2019-03-13
EP3452044A4 (en) 2020-04-22
SG11201810947PA (en) 2019-01-30
AU2021203748A1 (en) 2021-07-08
US20210078983A1 (en) 2021-03-18
IL280587B (en) 2021-10-31
WO2018002739A1 (en) 2018-01-04
AU2017286852A1 (en) 2019-01-17
BR112018076257A2 (pt) 2019-03-26
AU2017286852B2 (en) 2021-05-06
RU2019100713A (ru) 2020-07-28
US10858349B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
AU2023208158A1 (en) Compositions and methods for the treatment of cancer
WO2016046675A1 (en) Compositions and methods for the treatment of neurological diseases
WO2017090007A1 (en) Compositions and methods for the treatment of urea cycle disorders and hepatic diseases
US20160332950A1 (en) Compositions and methods for the treatment of urea cycle disorders and gout
AU2019313484A2 (en) Compositions and methods for the treatment of cancer
WO2016046674A1 (en) Compositions and methods for the treatment of moderate to severe pain
US9932294B2 (en) Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
NZ749512B2 (en) Compositions and methods for the treatment of cancer
EP3240779B1 (en) Compositions and methods for the treatment of epilepsy and neurological disorders
WO2017221083A1 (en) Compositions and methods for the treatment of viral infections
WO2014060942A2 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2016132186A1 (en) Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2016088132A9 (en) Compositions and methods for the treatment of multiple sclerosis
WO2016203337A2 (en) Compositions and methods for the treatment of cancer
WO2016203352A2 (en) Compositions and methods for the treatment of cancer
WO2016046670A1 (en) Compositions and methods for the treatment of renal diseases
WO2016046672A1 (en) Compositions and methods for the treatment of cardiovascular diseases and diabetes
WO2016067297A1 (en) Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy
WO2017037566A1 (en) Compound, composition and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510